Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin ...

Wegovy, Zepbound and similar medications all lead to metabolic improvements, but scientists are starting to unpick the ...

The growth of highly sought-after weight-loss drugs like Wegovy and Ozempic, otherwise known as GLP-1 medications, represents ...

The widespread use and enormous expense of blockbuster drugs like Wegovy are forcing state governments to make painful ...

and could help maintain lean muscle mass in the potentially millions of patients who may use GLP-1 drugs for obesity, the Jefferies analysts wrote. Zealand Pharma (ZLDPF) could add another novel ...

Weight loss drugs like Ozempic are all over the news. Here's what I'm reading to keep up as a health reporter.

The drug companies behind blockbuster weight loss and diabetes treatments have signaled that supply problems could soon be ...

down from a typical list price of $1,000-per-month for other, comparable anti-obesity drugs. "This a welcome first step for American families struggling to access these drugs," Biden said.

But does this new version of the drug come with its own costs? Zepbound is the latest drug to join the growing list of anti-obesity medications ... denied access to the essential treatment and ...

Eli Lilly said it has started selling single-dose vials of its popular weight-loss drug — and they cost 50% less than other obesity medicines. REUTERS Lilly and its Danish rival Novo Nordisk ...

While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market ... Jefferies analysts said in a research note Monday. With GLP-1 drugs set to generate north of $120 billion in annual ...